The overall methodological quality of the guidelines was low (using the AGREE II instrument, with mean overall score of 56%, SD=23%) (Supplemental Digital Content 2, http://links.lww.com/MLR/A559 for item and subscale scores). Thirteen (46%) guidelines did not report on the process used to generate recommendations. Patients or methodologists were not explicitly included in the guideline development process in 20 (71%) and 24 (86%) guidelines, respectively.
Guidelines most frequently offered recommendations about treatment goals: about glycemic control targets in 27 (96%) and about LDL-cholesterol targets in 20 (71%) guidelines. Fewer guidelines made recommendations taking into context the overall burden of treatment; for instance, 16 (57%) made recommendations about healthcare visit frequency (Table 1).
The main limitations of this work are that we used a rubric with only face validity to ascertain context and that we did not contact the guideline authors to uncover implicit considerations of context. The main strengths of our work include the reproducibility of our guideline inclusion, assessment of guideline quality and contextualization, use of a reproducible rubric, and the selection of contemporary guidelines in one of the chronic conditions receiving most quality-of-care attention. The rubric used here might be adaptable to other chronic conditions by substituting the condition-specific recommendations with ones pertinent to other conditions at hand (in terms of treatment goals and treatment burden) and scoring guidelines according to whether their recommendations take into account patient context (ie, comorbidities, socio-personal context, and patient preferences).
To our knowledge, this is among the first studies to systematically evaluate the extent to which diabetes management guidelines take into account patient context and consider how MCC might affect recommendations for patients with a common comorbidity. Many have commented, however, about the need to contextualize recommendations among patients with MCC.54–58 A recent review of Canadian clinical practice guidelines for high-prevalence conditions, including diabetes, hypertension, and dyslipidemia, found that comorbidities, barriers to implementation, and patient context such as life expectancy were given adequate consideration by only a minority of guidelines. Consistent with our findings, when recommendations were made in the guidelines, they were vague and nonspecific.54
One proposed explanation for the paucity of consideration given to patient context in guideline recommendations is that there might be an insufficient body of evidence to inform modification of single-disease recommendations when considering patients with complex contexts, such as patients with MCC. Clinical trials often exclude or underrepresent patients with certain comorbid conditions, and subgroup analyses are rarely conducted against socio-personal features. The role of personal preferences—particularly when competing priorities exist—also remains poorly studied. This might be limiting the ability of guideline developers to reach evidence-based conclusions that address these aspects of care.56,58 Tinetti et al6 have proposed a focus on patient-important outcomes as a way of harmonizing recommendations for patients with MCC; however, the most common recommendations in guidelines we reviewed have poor connection with such outcomes (ie, lowering HbA1c is not uniformly associated with improvements in functional capacity or symptom burden). Weak or tentative guideline recommendations take place when the trade-offs are unclear or when the pros and cons of alternative courses of action are closely matched. In these instances it is optimal to engage patients in the decision-making process. When guideline panels fail to detect these situations, they might instead frame them as technical “just do it” dictums that are often used to inform quality-of-care parameters and leave little room for patient involvement.56,58 This naturally leads to a tendency to “overtreat” or “treat to numbers,” which might cause more harm than good.56,58 A recent editorial has provided an extended example of how recommendations to achieve “tight” glycemic control might need to be modified to account for comorbidities, socio-personal context, and patient preferences.59
Other specific approaches to improve clinical practice guidelines by incorporating patient context and comorbidities have been proposed. For example, van Weel and Schellevis57 propose categorizing comorbidities as causal (diseases sharing a common pathophysiology), complicating (those that are disease specific), intercurrent (acute, interacting illnesses), and concurrent (no specific relation) in order to identify focus areas and separate comorbidities by the approach required to address them. Piette and Kerr61 offer a similar classification of comorbidities for people with diabetes as being dominant, concordant, discordant, symptomatic, and asymptomatic. Dominant comorbidities are those that command so much attention that they overshadow diabetes (eg, cancer, cognitive impairment). Concordant comorbidities (similar to those classified by van Weel and Schellevis as “causal”) share the same pathophysiology as diabetes and fit in the management plan for diabetes (eg, hypertension, peripheral vascular disease). In contrast, discordant comorbidities (similar to those referred to as “concurrent” by van Weel and Schellevis) are unrelated to diabetes in their pathophysiology or management (eg, chronic back pain, asthma). With symptomatic comorbidities (eg, depression, gastroesophageal reflux disease), the main focus is on symptom management and quality of life, although limited attention may be given to prevention of long-term complications. In contrast, the focus on asymptomatic comorbidities (eg, hypertension, hyperlipidemia) is solely on preventing long-term complications.61
Calculating and reporting a “payoff time” for guideline recommendations, over which a patient must comply with the guideline so as to achieve the proposed benefit, has also been proposed in order to help patients weigh guideline compliance with their comorbidities and personal context.55 As an example, a patient with limited life expectancy having difficulty maintaining tight glycemic control on oral antihyperglycemic pharmacotherapy should balance the payoff time for tight glycemic control with insulin to prevent long-term complications of diabetes with the burden and cost of regular blood glucose monitoring, risk of hypoglycemia, and the cost of the insulin regimen required. If the payoff time is greater than the patient’s life expectancy, a discussion in the context of shared decision making about foregoing insulin therapy may lead to a decreased burden of treatment with a corresponding increase in quality of life, improved cost-benefit, and more patient-centered care.
Although some have suggested the development of guidelines focused on specific population subsets (eg, patients with a disease plus specific comorbidities), it is unrealistic to develop guidelines that cover every possible permutation of patient circumstances, especially in the case of multimorbidity and preference-sensitive decisions.57 Instead, clinical practice guidelines must take a holistic approach, which provides practical guidance clinicians can use to individualize care while focusing on patient-important rather than disease-centered outcomes.6,57 Individualization of care to incorporate patient context and preferences necessitates patient participation in decision making. Guidelines should offer tentative recommendations when these might apply to patients with MCC, opening the space for conversations with patients and shared decision making.62,63 In the absence of these enlightened approaches, high-fidelity adherence to current guidelines results in an overwhelming number of clinical actions and an absurd accumulation of work and complexity to which clinicians and patients can only respond with noncompliance.
Although algorithmic guidelines are relatively simple to implement, individualized care is less straightforward, as there is little guidance to help clinicians individualize care.64 Although there is limited evidence in the literature on ways to improve outcomes for patients with complex contexts, including MCC,13 we urge those developing guidelines for chronic conditions to consider patient context in every recommendation they make and to offer specific modifications (in action, timing, or intensity) based on comorbidities, socio-personal context, and patient preferences.
Extant clinical practice guidelines for one chronic disease sometimes consider the context of the patient with that disease but do so narrowly and infrequently. Guideline panels must remove their contextual blinders if they want to practically guide the care of patients with MCC.
The authors thank Larry Prokop at the Mayo Clinic Libraries for assistance in conducting the literature search. The authors also acknowledge Hannah Fields for her contribution to the screening process.
1. Herman WH, Hoerger TJ, Brandle M, et al..The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes
in adults with impaired glucose tolerance.Ann Intern Med.2005;142:323–332.
3. May C, Montori VM, Mair FS.We need minimally disruptive medicine
4. Shippee ND, Shah ND, May CR, et al..Cumulative complexity: a functional, patient-centered model of patient complexity can improve research and practice.J Clin Epidemiol.2012;65:1041–1051.
5. Vijan S, Hayward RA, Ronis DL, et al..Brief report: the burden of diabetes
therapy: implications for the design of effective patient-centered treatment regimens.J Gen Intern Med.2005;20:479–482.
6. Tinetti ME, Bogardus ST Jr, Agostini JV.Potential pitfalls of disease-specific guidelines for patients with multiple conditions.N Engl J Med.2004;351:2870–2874.
9. Huang ES, Brown SE, Ewigman BG, et al..Patient perceptions of quality of life with diabetes
-related complications and treatments.Diabetes
10. Fried TR, McGraw S, Agostini JV, et al..Views of older persons with multiple morbidities on competing outcomes and clinical decision-making.J Am Geriatr Soc.2008;56:1839–1844.
11. Struijs JN, Baan CA, Schellevis FG, et al..Comorbidity in patients with diabetes mellitus
: impact on medical health care utilization.BMC Health Serv Res.2006;6:84.
12. Phillips LS, Branch WT, Cook CB, et al..Clinical inertia.Ann Intern Med.2001;135:825–834.
13. Smith SM, Soubhi H, Fortin M, et al..Interventions for improving outcomes in patients with multimorbidity in primary care and community settings.Cochrane Database Syst Rev.2012;4:CD006560.
14. Eton DT, Ramalho de Oliveira D, Egginton JS, et al..Building a measurement framework of burden of treatment in complex patients with chronic conditions: a qualitative study.Patient Relat Outcome Meas.2012;3:39–49.
15. Heisler M, Bouknight RR, Hayward RA, et al..The relative importance of physician communication, participatory decision making, and patient understanding in diabetes
self-management.J Gen Intern Med.2002;17:243–252.
16. Weiner SJ, Schwartz A, Sharma G, et al..Patient-centered decision making and health care outcomes: an observational study.Ann Intern Med.2013;158:573–579.
17. .Crossing the Quality Chasm: A New Health System for the 21st Century.Washington, DC: The National Academies Press; 2001.
18. Tinetti ME, Fried TR, Boyd CM.Designing health care for the most common chronic condition—multimorbidity.JAMA.2012;307:2493–2494.
19. Andrews J, Guyatt G, Oxman AD, et al..GRADE guidelines: 15. Going from evidence to recommendations: the significance and presentation of recommendations.J Clin Epidemiol.2013;66:719–725.
21. Guyatt GH, Haynes RB, Jaeschke RZ, et al..Users’ Guides to the medical literature: XXV. Evidence-based medicine: principles for applying the Users’ Guides to patient care. Evidence-Based Medicine Working Group.JAMA.2000;284:1290–1296.
22. Murad MH, Montori VM, Guyatt GH.Incorporating patient preferences in evidence-based medicine.JAMA.2008;300:2483author reply 2483-2484.
25. Moher D, Liberati A, Tetzlaff J, et al..Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.PLoS Med.2009;6:e1000097.
26. Alsafadi H, Morrissey J, Patel V.The updated Alphabet Strategy: facilitating the implementation of NICE guidelines.Diabetes
27. .Standards of medical care in diabetes
management in correctional institutions.Diabetes
30. Bantle JP, Wylie-Rosett J, Albright AL, et al..Nutrition recommendations and interventions for diabetes
: a position statement of the American Diabetes
31. Bruno G, De Micheli A, Frontoni S, et al..Highlights from “Italian Standards of care for Diabetes Mellitus
2009-2010”.Nutr Metab Cardiovasc Dis.2011;21:302–314.
32. Handelsman Y, Mechanick JI, Blonde L, et al..American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus
comprehensive care plan.Endocr Pract.2011;17suppl 21–53.
33. .Global guideline for type 2 diabetes
: recommendations for standard, comprehensive, and minimal care.Diabet Med.2006;23:579–593.
34. Jellinger PS, Davidson JA, Blonde L, et al..Road maps to achieve glycemic control in type 2 diabetes mellitus
: ACE/AACE Diabetes
Road Map Task Force.Endocr Pract.2007;13:260–268.
35. Guzman JR, Lyra R, Aguilar-Salinas CA, et al..Treatment of type 2 diabetes
in Latin America: a consensus statement by the medical associations of 17 Latin American countries. Latin American Diabetes
Association.Rev Panam Salud Publica.2010;28:463–471.
36. Ko SH, Kim SR, Kim DJ, et al..2011 clinical practice guidelines for type 2 diabetes
37. Leszczyszyn-Pynka M, Pynka S.Management of the blood glucose abnormalities in HIV-infected Patients.HIV AIDS Rev.2006;5:25–27.
38. Amod A, Ascott-Evans B, Berg G, et al..The 2012 SEMDSA guideline for the management of type 2 diabetes
.J Endocrinol Metab Diabetes
39. Matthaei S, Bierwirth R, Fritsche A, et al..Medical antihyperglycaemic treatment of type 2 diabetes mellitus
: update of the evidence-based guideline of the German Diabetes
Association.Exp Clin Endocrinol Diabetes
40. Maynard G, Wesorick DH, O’Malley C, et al..Subcutaneous insulin order sets and protocols: effective design and implementation strategies.J Hosp Med.2008;3suppl29–41.
44. Nathan DM, Buse JB, Davidson MB, et al..Management of hyperglycemia in type 2 diabetes
: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes
Association and the European Association for the Study of Diabetes
46. Qaseem A, Humphrey LL, Sweet DE, et al..Oral pharmacologic treatment of type 2 diabetes mellitus
: a clinical practice guideline from the American College of Physicians.Ann Intern Med.2012;156:218–231.
48. Rodbard HW, Jellinger PS, Davidson JA, et al..Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus
: an algorithm for glycemic control.Endocr Pract.2009;15:540–559.
49. Rydén L, Standl E, Bartnik M, et al..Guidelines on diabetes
, and cardiovascular diseases: full text.Eur Heart J Suppl.2007;9suppl CC3–C74.
51. Sigal RJ, Kenny GP, Wasserman DH, et al..Physical activity/exercise and type 2 diabetes
: a consensus statement from the American Diabetes
52. Menendez Torre E, Lafita Tejedor J, Artola Menendez S, et al..Recommendations for the pharmacologic treatment of hyperglycemia in type 2 diabetes
. Consensus document.Nefrologia.2011;31:17–26.
54. Mutasingwa DR, Ge H, Upshur RE.How applicable are clinical practice guidelines to elderly patients with comorbidities
?Can Fam Physician.2011;57:e253–e262.
55. Braithwaite RS, Concato J, Chang CC, et al..A framework for tailoring clinical guidelines to comorbidity at the point of care.Arch Intern Med.2007;167:2361–2365.
56. Fitzgerald SP, Bean NG.An analysis of the interactions between individual comorbidities
and their treatments—implications for guidelines and polypharmacy.J Am Med Dir Assoc.2010;11:475–484.
57. van Weel C, Schellevis FG.Comorbidity and guidelines: conflicting interests.Lancet.2006;367:550–551.
58. .Patient-centered care for older adults with multiple chronic conditions: a stepwise approach from the American Geriatrics Society.J Am Geriatr Soc.2012;60:1957–1968.
59. Lipska KJ, Montori VM.Glucose control in older adults with diabetes mellitus
-more harm than good?: comment on “The association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus
”.JAMA Intern Med.2013;10:1–2.
60. Andrews J, Guyatt G, Oxman AD, et al..GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations.J Clin Epidemiol.2013;66:719–725.
61. Piette JD, Kerr EA.The impact of comorbid chronic conditions on diabetes
62. Jaeschke R, Guyatt GH, Dellinger P, et al..Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive.BMJ.2008;337:a744.
63. Stiggelbout AM, Van der Weijden T, De Wit MP, et al..Shared decision making
: really putting patients at the centre of healthcare.BMJ.2012;344:e256.
64. Weiner SJ, Schwartz A, Weaver F, et al..Contextual errors and failures in individualizing patient care: a multicenter study.Ann Intern Med.2010;153:69–75.